First test of new drug for stubborn blood cancer
NCT ID NCT04405167
Summary
This early-stage study aimed to find the safest dose of a drug called tasquinimod for people with multiple myeloma that has come back or stopped responding to treatment. Researchers tested tasquinimod by itself and combined with a standard three-drug regimen. The main goal was to understand side effects and see if the drug showed any early signs of fighting the cancer. The trial was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.